piperaquine has been researched along with zithromax in 5 studies
Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (zithromax) | Trials (zithromax) | Recent Studies (post-2010) (zithromax) |
---|---|---|---|---|---|
638 | 227 | 497 | 6,964 | 1,263 | 3,790 |
Protein | Taxonomy | piperaquine (IC50) | zithromax (IC50) |
---|---|---|---|
30S ribosomal protein S6 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 0.3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Davis, TM; Hackett, SL; Ilett, KF; Karunajeewa, HA; Lautu, D; Mueller, I; Siba, P; Tavul, L; Wong, RP | 1 |
Auyeung, SO; Batty, KT; Benjamin, JM; Davis, TM; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM; Yadi, G | 1 |
Agarwal, P; Anvikar, AR; Pillai, CR; Srivastava, K | 1 |
Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G | 1 |
Alifrangis, M; Ashorn, U; Barsosio, HC; Chico, RM; Dodd, J; Gesase, S; Gutman, JR; Hansson, H; Hill, J; Kariuki, S; Kavishe, RA; Klein, N; Lusingu, JPA; Madanitsa, M; Magnussen, P; Maleta, K; Minja, DTR; Mosha, JF; Msemo, OA; Mtove, G; Mukerebe, C; Mwapasa, V; Onyango, ED; Otieno, K; Phiri, KS; Saidi, Q; Schmiegelow, C; Ter Kuile, FO; Wang, D | 1 |
2 trial(s) available for piperaquine and zithromax
Article | Year |
---|---|
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Erythrocytes; Female; Gestational Age; Humans; Live Birth; Malaria, Falciparum; Malaria, Vivax; Papua New Guinea; Parasitemia; Plasmodium falciparum; Plasmodium vivax; Pregnancy; Pyrimethamine; Quinolines; Random Allocation; Severity of Illness Index; Stillbirth; Sulfadoxine | 2019 |
Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled tr
Topics: Adult; Antimalarials; Azithromycin; Drug Combinations; Female; Humans; Infant, Newborn; Kenya; Pregnancy; Pregnancy Complications, Parasitic; Pregnancy Outcome; Pyrimethamine; Quinolines; Sulfadoxine; Tanzania; Young Adult | 2023 |
3 other study(ies) available for piperaquine and zithromax
Article | Year |
---|---|
In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea.
Topics: Amodiaquine; Antimalarials; Artemisinins; Azithromycin; Child; Child, Preschool; Drug Resistance, Multiple; Female; Humans; Infant; Inhibitory Concentration 50; L-Lactate Dehydrogenase; Male; Mefloquine; Membrane Transport Proteins; Naphthoquinones; Plasmodium falciparum; Protozoan Proteins; Quinolines; Threshold Limit Values | 2010 |
Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Azithromycin; Biological Availability; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Therapy, Combination; Female; Humans; Malaria, Falciparum; Mass Spectrometry; Models, Biological; Papua New Guinea; Pregnancy; Pregnancy Complications, Parasitic; Pregnancy Outcome; Quinolines; Young Adult | 2016 |
Topics: Anti-Bacterial Agents; Antimalarials; Artemether; Artemisinins; Atovaquone; Azithromycin; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Humans; India; Lumefantrine; Malaria, Falciparum; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2017 |